Capricor Therapeutics, Inc. ( CAPR ) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-label extension study with CAP-1002.

HOPE-2, a Phase 2 clinical study, assessed Capricor’s CAP-1002 therapy in boys and young men with DMD. According to results, patients treated with CAP-1002 continued to show benefits after 3 years of treatment when compared to an external comparator dataset of similar DMD patients.

“I am extremely encouraged by these positive results from our HOPE-2 OLE study which continue to support the long-term impact of CAP-1002 for the treatment of DMD,” said Linda Marbán, Ph.D., Capricor’s CEO.

The study is currently ongoing and will enter its fourth year.

Capricor Therapeutics ( CAPR ) plans to present these results at the Parent Project Muscular Dystrophy 30th Annual Conference being held June 27-29, 2024.

Related Link: Expert Outlook: TransMedics Gr Through The Eyes Of 7 Analysts

CAPR Price Action: At the time of publication, Capricor Therapeutics ( CAPR ) shares are trading 4.43% higher at $5.89 per data from Benzinga Pro.

Image: 7433388 from Pixabay.